Pfizer is partnering with Merck to test a combination of 3 experimental cancer drugs for the treatment of solid tumours in an early-stage clinical trial. The cocktail of 3 immunotherapies uses Merck’s PD-L1 treatment, avelumab, and two further treatments; uomilumab and another code-named OX40. This early-stage clinical trial will be one of the first to test 3 immunotherapies at the same time to work out whether the combination of these drugs can safely shrink solid tumours.

Read more here Read a second article about Pfizer’s oncology research here.